title: Importance of cost-effectiveness and value in cancer care and healthcare policy.
abstract: The cost of cancer care has increased by five fold over the last three decades. As our healthcare system shifts from volume to value, greater scrutiny of interventions with clinical equipoise is required. Traditionally, QALYs and ICER have served as surrogate markers for value. However, this approach fails to incorporate all stakeholders' viewpoints. Prostate cancer, low risk DCIS, and thyroid cancer are used as a framework to discuss value and cost-effectiveness. J. Surg. Oncol. 2016;114:275-280. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Ravinder
authors.initials: R
authors.lastname: Kang
authors.affiliation: Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Philip P
authors.initials: PP
authors.lastname: Goodney
authors.affiliation: Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Sandra L
authors.initials: SL
authors.lastname: Wong
mesh_terms: D001943:Breast Neoplasms / Q000191:economics / Q000628:therapy*; D003362:Cost-Benefit Analysis; D005260:Female; D006291:Health Policy; D006801:Humans; D008297:Male; D017063:Outcome Assessment, Health Care; D011471:Prostatic Neoplasms / Q000191:economics / Q000628:therapy*; D019057:Quality-Adjusted Life Years; D013964:Thyroid Neoplasms / Q000191:economics / Q000628:therapy*
keywords: ICER; QALY; ductal carcinoma in-situ; prostate cancer; thyroid cancer; value